ONLINE DATA SUPPLEMENT

SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae

Tomasicchio M^{1,2}, Jaumdally S^{1,2}, Pooran A^{1,2}, Esmail A^{1,2}, Wilson L^{1,2}, Kotze A^{1,2}, Semple L^{1,2}, Meier S^{1,2}, Pillay K⁵, Roberts R⁵, Kriel R⁵, Meldau R^{1,2}, Oelofse S^{1,2}, Mandviwala C^{1,2}, Burns J^{1,2}, Londt R^{1,2}, Davids M^{1,2}, van der Merwe^{1,2} C, Roomaney A^{1,2}, Kühn L^{1,2}, Perumal T^{1,2}, Scott A.J^{1,2}, Hale M.J⁶, Baillie V⁷, Mahtab S⁷, Williamson C⁸, Joseph R⁸, Sigal A⁹, Joubert I¹⁰, Piercy J¹⁰, Thomson D¹⁰, Fredericks DL¹⁰, Miller MGA¹⁰, Nunes M⁷, Madhi S.A⁷, Dheda K^{1,2,3,4}.

¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.

²South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

³Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

⁴Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.

⁵ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town, South Africa

⁶ Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand.

⁷ South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

⁸ Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

⁹ Africa Health Research Institute, Durban, South Africa.

¹⁰ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University of Cape Town, South Africa

Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South Africa. E-mail: keertan.dheda@uct.ac.za

Supplementary methods.

Sample size.

Samples sizes were calculated based on our primary endpoint measure i.e. the proportion of nasopharyngeal versus organ biopsy samples that were viral culturepositive. Based on the literature, viral replication can be demonstrated by culture approximately up to about 14 days post symptom onset. At ~14 days post symptom-onset, assuming a nasopharyngeal viral culture positivity rate of 5% or less and lung biopsy positivity rate of $\sim 40\%$, a case to control ratio of 2:1, ~ 40 lung biopsy samples and ~20 controls, would allow us to detect a significant difference in groups at an alpha of 0.05 and with 80% power (OpenEpi, Version 3, opensource calculator). Thus, we were powered to detect a \sim 35% difference between the groups.



Figure S1. In vitro culture of SARS-CoV-2. (A) Light microscope images showing SARS-CoV-2 viral-induced cytopathic effects (red arrow). (B) Confocal microscopy showing SARS-CoV-2 (red) infecting the cell line. DAPI (blue) was used as the nuclear stain. (C) The limit of detection (LOD) for the PCR assay to detect replicating competent SARS-CoV-2. SARS-CoV-2 viral stock was diluted in 10-fold dilutions from 1×10⁵ to 1 copy/ml and co-cultured with confluent H1299 ACE2 cells in a 24-well plate for 9 days. Aliquots were analysed by PCR for viral load on days 1, 3, 6 and 9. The relative viral load (copies/ml) are shown. The dotted line represents the LOD for viral load $(1 \times 10^{11} \text{ Jm})$ copies/ml).

Supplementary results.

Table S1. Demographic and clinical characteristics of the decedents.

	All Patients	Lung biopsy	Lung biopsy	[#] p-value
	n=42	culture-positive	culture-negative	
		n=16	n=26	0.504
Gender	47 (0) (0) (40)	12.00/ (7/1.0)	500((12/26)	0.694
Male	47.6% (20/42)	43.8% (7/16)	50% (13/26)	
Female	52.3% (22/42)	56.3% (9/16)	50% (13/26)	
Median age in years	53 (41-62)	58.5 (45.5-64)	49.5 (41-60)	0.2
(range)				
Admission to ICU				
*BMI status				
Underweight	37.5% (9/24)	25% (2/8)	43.8% (7/16)	0.371
Normal	25% (6/24)	25% (2/8)	25% (4/16)	-
Overweight	25% (6/24)	25% (2/8)	12.5% (3/16)	0.722
Obese	4% (1/24)	12.5% (1/8)	5% (1/16)	0.602
Morbidly obese	12.5% (3/24)	12.5% (1/8)	6% (1/16)	0.602
Unknown	83.3% (20/24)	62.5% (5/8)	93.8% (15/16)	0.053
*Co- morbidities				
COPD/Chronic bronchitis	16.6% (4/24)	12.5% (1/8)	18.8% (3/16)	0 699
Obesity	41.7% (10/24)	50% (4/8)	37.5% (6/16)	0.558
Diabatas	16.6% (1/24)	25% (2/8)	12.5% (2/16)	0.540
Cancer	33 3% (8/24)	12.5%(1/8)	43.8% (7/16)	0.126
	9.20/ (0/24)	12.5% (1/0)	43.870 (7/10)	0.120
Hypertension	8.3% (2/24)	12.5% (1/8)	6% (1/16)	0.602
Smoker	29.2% (7/24)	0% (0/8)	50% (7/16)	0.026
³² Other	4% (1/24)	0% (0/8)	6% (1/16)	0.470
	14.00/ (6/40)	10.00/ (0/1.6)	11.50((2.2.5)	0.515
HIV-positive	14.3% (6/42)	18.8% (3/16)	11.5% (3/26)	0.517
•Vaccination status		0.04 (0.10)	10.004 (0.41.6)	0.100
Yes	12.5% (3/24)	0% (0/8)	18.8% (3/16)	0.190
No	87.5% (21/24)	100% (8/8)	81.2% (13/16)	0.190
Smoking status				
Current smoker	2.4% (1/42)	6.3% (1/16)	0% (0/26)	0.197
Ex-smoker	9.5% (4/42)	12.5% (2/16)	7.7% (2/26)	0.606
Never smoked	31% (13/42)	37.5% (6/16)	27% (7/26)	0.472
Unknown	31% (13/42)	31.3% (5/16)	30.8% (8/26)	0.974
SARS-CoV-2 variant				
detected in the Beta group				
by whole genome				
sequencing				
Beta B1.1.448	12.5% (1/8)	12.5% (1/8)	-	-
Beta V2	25% (2/8)	25% (2/8)	-	-
Unknown*	83.3% (15/18)	62.5% (5/8)	100% (10/10)	-
SARS-CoV-2 variant				
detected in the Delta group				
by whole genome				
sequencing	40/ (1/04)	10 50/ (1/0)	00/ (0/1 5)	0.140
Aipha V I	4% (1/24)	12.5% (1/8)	0% (0/16)	0.149

Beta V2	4% (1/24)	0% (0/8)	6.3% (1/16)	0.470
Delta 21J	29.2% (7/24)	25% (2/8)	31.3% (5/16)	0.751
Unknown◆	62.5% (15/24)	50% (4/8)	68.8% (11/16)	0.371
Secondary bacterial infection present (Biofire multiplex PCR)				
Yes	40.5% (17/42)	50% (8/16)	34.6% (9/26)	0.324
No	40.5% (17/42)	37.5% (6/16)	42.3% (11/26)	0.758
None detected	16.7% (7/42)	12.5% (2/16)	19.2% (5/26)	0.570
Unknown	2.4% (1/42)	0% (0/16)	3.8% (1/26)	0.427
Bacterial bronchopneumonia (microbiologically and histopathologically confirmed)	11% (4/38)	21% (3/14)	4% (1/24)	0.129
Sterold usage				
Yes	79.5 % (33/42)	62.5% (10/16)	88.5% (23/26)	0.047
No	21.4% (9/42)	37.5% (6/16)	11.5% (3/26)	0.047
Median days of steroid usage (IQR)	8 days (4.5- 12) n=24	4.5 days (2.5-6.5) n=8	8 days (4.5-12) n=16	0.015
COVID-19 status at admission as assessed by nasopharyngeal swab PCR				
PCR positive	90.5% (38/42)	93.8% (15/16)	88.5% (23/26)	0.571
COVID-19 antigen positive (no PCR result)	7.1% (3/42)	6.3% (1/16)	11.5% (3/26)	0.571
Unknown	2.4% (1/42)	0% (0/16)	3.8% (1/26)	0.427
Median Ct (IQR)	26.1 (21.6- 28.3) n=27	26.3 (20.9-28.3) n=11	25.6 (23.4-29.7) n=16	0.429
Ct value unknown	n=11	n=4	n=7	
COVID-19 status at time of MITS as assessed by				
PCR positive	85.7% (36/42)	100% (16/16)	76.9% (20/26)	0.038
PCR negative	14.3% (6/42)	0% (0/16)	23.1% (6/26)	0.038
Median Ct (IQR)	23.5 (20.5- 29.9) n=33	23.5 (17.7-25.6) n=15	26.2 (21.4-30.1) n=18	0.166
Ct value unknown	n=9	n=1	n=8	
Median time from onset of symptoms to death (range)	17 (4-58) n=42	15 (5-27) n=16	18 (4-58) n=26	0.112
Median days from admission to ICU to death	5 days (1-48) n=42	3 days (1-17) n=16	8 days (0-48) n=26	0.061

(range)				
Median days from	11 days (1-	7 days (1-17)	13 days (5-24)	0.053
administration of high	24)	n=7	n=16	
flow nasal oxygen to death	n=23 △			
(range)				

[#]p-values are for comparison between lung culture-positive and negative.

*BMI status was only recorded for the Delta group.

*Co-morbidities were only recorded for the Delta group. No patients had asthma, current TB, other chronic lung disease,

cardiovascular disease, CVA/stroke, malnutrition, organ failure/disease, anaemia or epilepsy.

* Vaccination status was only recorded for the Delta group.

 $^{\Omega}$ Patients with dyslipidemia/varicose veins, ex-smoker, previous lateral medullary syndrome, previous heavy alcohol use, ischemic heart disease or trisomy.

⁷Ct value at day of MITS sampling missing for 9 patients.

• Either the viral load was too low or the sample was not available.

^{Δ} Only recorded for the Delta group.

Α

Lung biopsy viral culture in the Beta and Delta cohort

Proportion of nasopharyngeal swabs that are culturepositive at diagnosis (~5 days from symptom onset), 12 and 19 days from symptom onset in ambulatory patients



В

Figure S2. *In vitro* viral culture of lung biopsies from MV decedents (A) and nasopharyngeal swabs from ambulatory control (B). (A) Description of a new SARS-CoV-2 human biophenotype that has ongoing viral replication in lung for up to 27 days post symptom onset. (B) Ambulatory patients do not have active replication competent SARS-CoV-2 in their NPS on day 19 post-symptom onset. The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The lung biopsy samples were removed and placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator and viral replication were monitored on days 1, 3, 6 and 9 by PCR. DSOTD=days symptom onset to death.

56% of nasopharyngeal swabs (URT) from ambulatory patients were culture-positive at diagnosis (~5 days from symptom onset; Figure S2B) and the proportion of nasopharyngeal swabs that remained culture-positive beyond 12 days post symptom onset was low, at 5.5% (p=0.001) compared to 38% (p=0.038) for the lung biopsies (LRT) from the MV decedents (Figure 2B and S2B).



Figure S3. Previously ventilated decedents had active replicating virus in the upper respiratory tract for up to 27 days post symptom onset to death. (A) The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The nasopharyngeal swabs in universal transport medium were initially filtered through a 0.22µm filter prior to inoculation. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO₂ and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown. The dotted lines represent the median days from symptom onset to death for the lung culture-negative (-ve; green) and culture-positive (18 days) decedents. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown for the Beta (**B**) and Delta (**C**) cohorts. The median days from symptom onset to death for the culture-negative (10.5 days for the Beta cohort and 23.5 days for the Delta cohort) participants are shown.

Similarly, to the lung culture data, we show that overall, the nasopharyngeal swab culture-positive group had accelerated death (13 day from symptom onset to death) compared to the lung culture-negative group (18 days from symptom onset to death; Figure S3B; p=0.017).



Figure S4. The culture-positive participants from the Delta cohort, but not the Beta cohort, had a higher frequency of secondary bacterial infection compared to the culture-negative participants.



Figure S5. Electron micrographs of key clinical features of lung abnormalities associated with acute COVID-19 disease.



Figure S6. Flow cytometry data showing (A) the gating strategy and expression of IFN- γ , TNF- α , IL-2 and IL- β from CD4+ (B) and CD8+ (C) lung-derived T-cells from the Delta decedents.

Table S2. Histopathological data of the combined study cohort.

Histology Tissue	All patients	culture-	culture-	p-value
	n=33*	positive patients	negative patients	•
LING		n=13	n=20	
LUNG	24/22(720/)	<u> 9/12</u>	16/20 (800/)	0.245
Alveolar hyanne memoranes	24/33 (73%)	6/15 (61.5%)	10/20 (80%)	0.243
Interstitial oedema	7/19 (37%)	(01.5%)	4/12 (33%)	0.678
Collapsed alveoli	9/33 (27%)	3/13 (23%)	6/20 (30%)	0.673
Proumocyte depudation/necrosis	21/33(730/2)	0/13	15/20 (75%)	0.716
r neumocyte denudation/nectosis	24/33 (1370)	(69.2%)	13/20 (73%)	0.710
Endothelial necrosis	5/19 (26%)	3/7 (43%)	2/12 (17%)	0.211
Vascular neutrophil aggregate	6/19 (32%)	3/7 (43%)	3/12 (25%)	0.419
Micro-thromboembolic	11/33 (33%)	5/13	6/20 (30%)	0.614
		(38.5%)		
Pulmonary haemorrhage	14/33 (42%)	3/13 (23%)	11/20 (55%)	0.070
Pulmonary endothelialitis	5/19 (26%)	2/7 (29%)	3/12 (25%)	0.865
Organising hyaline membranes	15/19 (79%)	6/7 (86%)	9/12 (75%)	0.581
Fibroblasts/myofibroblasts proliferation	16/19 (84%)	6/7 (86%)	10/12 (83%)	0.891
Lymphocytic infiltration	26/33 (79%)	9/13	17/20 (85%)	0.279
Plasma cell infiltration	4/19 (21%)	(09.2%)	3/12 (25%)	0.581
Type II pneumocytes proliferation	30/33 (91%)	10/13	$\frac{3}{12}(23\%)$	0.381
Type II pleatilocytes promeration	50/55 (7170)	(77%)	20/20 (100 %)	0.024
Atypical pneumocytes	18/19 (95%)	7/7 (100%)	11/12 (92%)	0.433
Atypical pneumocyte cytomegaly	25/33 (76%)	9/13 (69%)	16/20 (80%)	0.481
Atypical pneumocyte nucleomegaly	21/33 (64%)	7/13 (54%)	14/20 (70%)	0.346
Atypical pneumocyte multinucleation	19/33 (58%)	6/13 (46%)	13/20 (65%)	0.285
Atypical pneumocyte syncytia	5/33 (15%)	3/13 (23%)	2/20 (10%)	0.306
Foamy pneumocytes	19/19 (100%)	7/7 (100%)	12/12 (100%)	-
Arterial/arteriole thrombosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Diffuse collagenous fibrosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Subpleural/interstitial fibrosis	7/19 (37%)	2/7 (29%)	5/12 (42%)	0.568
Honeycomb	5/33 (15%)	$\frac{2}{15}$	4/20 (20%)	0.737
Traction bronchiectasis	0/19 (0%)	(13.4%)	0/12 (0%)	_
Squamous met	1/19 (5%)	1/7 (14%)	0/12 (0%)	0.363
Intimal fibrosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Medial hypertrophy	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Organising pneumonia	10/33 (30%)	4/13 (31%)	6/20 (30%)	0.963
Bronchopneumonia (neutrophilic infiltrate	10/33 (30%)	5/13	5/20 (25%)	0.411
into the alveoli)		(38.5%)		
Intranuclear inclusions	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Intracytoplasmic inclusions	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Megakaryocytes	22/33 (68%)	8/13 (71%)	14/20 (70%)	0.614
Lung naemophagocytosis (increased	17/33 (52%)	3/13 (23%)	14/20(70%)	0.008
Lung siderophages	6/33 (18%)	2/13	4/20 (20%)	0.737
Lung siderophages	0/33(1870)	(15.4%)	4/20 (20%)	0.737
Necrotising granulomas	1/33 (3%)	1/13 (0%)	0/20(7.7%)	0.208
Non-necrotising granulomas	0/33 (0%)	0/13(0%)	0/20 (0%)	-
HEART				
Isolated myocyte necrosis	6/33 (18%)	1/13 (14%)	5/20 (25%)	
Cardiac ischaemia	8/17 (47%)	3/7 (43%)	5/10 (50%)	0.772
Cardiac thrombi	1/33 (3%)	0/13 (0%)	1/20 (5%)	0.413
Card capillary neutrophil margination	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
RBC fragment	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Lipofuscin	17/17 (100%)	7/7 (100%)	10/10 (100%)	-
Enlarged nuclei	23/33 (70%)	10/13 (77%)	13/20 (65%)	0.467
Cardiac interstitial fibrosis	20/33 (61%)	4/13 (31%)	16/20 (80%)	0.005
Heart endothelialitis	1/33 (3%)	0/13 (0%)	1/20 (10%)	0.413

			1	
Cardiac neutrophils	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Cardiac lymphocytes	5/33 (15%)	1/13 (7.7%)	4/20 (20%)	0.335
Cardiac histiocytes	2/33 (6%)	1/13 (7.7%)	1/20 (5%)	0.752
Cardiac eosinophils	1/33 (3%)	0/13 (0%)	1/20 (5%)	0.413
Cardiac interstitial oedema	4/33 (12%)	0/13 (0%)	4/20 (20%)	0.085
LIVER				
Increase Kupffer	16/17 (94%)	7/7 (100%)	9/10 (90%)	0.389
Foamy Kupffer	4/17 (24%)	1/7 (14%)	3/10 (30%)	0.452
Liver haemophagocytosis	9/33 (27%)	4/13 (31%)	5/20 (25%)	0.716
Liver siderophages	1/33 (3%)	0/13 (0%)	1/20 (5%)	0.413
Liver necrosis	7/17 (41%)	3/7 (43%)	4/10 (40%)	0.906
Spotty necrosis Zone 1	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Spotty necrosis zone 2	2/16 (13%)	1/6 (17%)	1/10 (10%)	0.696
Spotty necrosis Zone 3	2/17 (12%)	1/7 (14%)	1/10 (10%)	0.787
Confluent necrosis zone 1	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Confluent necrosis Zone 2	1/17 (6%)	0/7 (0%)	1/10 (10%)	0.389
Confluent necrosis Zone 3	4/17 (24%)	1/7 (14%)	3/10 (30%)	0.452
Micro steatosis	14/17 (82%)	6/7 (86%)	8/10 (80%)	0.761
Macro steatosis	13/17 (76%)	6/7 (86%)	7/10 (70%)	0.452
Cholestasis	8/33 (24%)	3/13 (23%)	5/20 (25%)	0.900
Liver inflammation	9/17 (53%)	3/7 (43%)	6/10 (60%)	0.060
Liver regeneration	16/17 (94%)	7/7 (100%)	9/10 (90%)	0.389
Liver congestion	9/33 (%)	8/13	11/20 (55%)	0.710
U	× ,	(61.5%)	~ /	
Liver viral inclusions	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Liver fibrosis F1	2/17 (12%)	1/7 (14%)	1/10 (10%)	0.787
Liver fibrosis F2	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Liver fibrosis F3	1/17 (6%)	0/7 (0%)	1/10 (10%)	0.389
Liver fibrosis F4	1/17 (6%)	0/7 (0%)	1/10 (10%)	0.389
Primary sclerosing cholangitis	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Primary biliary cholangitis	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Extramedullary haematopoiesis (EMH)	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
KIDNEY			, ,	
Glom capillary dilatation	10/11 (91%)	5/5 (100%)	5/6 (83%)	0.338
Glom thrombus	4/11 (36%)	0/5 (0%)	4/6 (67%)	0.022
Glom sclerosis	3/11 (27%)	0/5 (0%)	3/6 (50%)	0.064
Increase mesangium	7/11 (64%)	3/5 (60%)	4/6 (67%)	0.819
Membrane thickening	0/11 (0%)	0/5 (0%)	0/6 (0%)	-
Acute kidney injury	4/11 (36%)	0/5 (0%)	4/6 (67%)	0.022
Tubular casts	6/11 (55%)	2/5(40%)	4/6 (67%)	0.377
Isometric vacuole	0/11 (0%)	0/5 (0%)	0/6(0%)	-
Kidney interstitial lymphocytes	1/11 (9%)	1/5 (20%)	0/6(0%)	0.251
Kidney interstitial plasma	1/11 (9%)	1/5 (20%)	0/6 (0%)	0.251
Kidney interstitial fibrosis	2/11 (18%)	0/5(0%)	2/6 (33%)	0.154
Kidney interstitial haem	0/11 (0%)	0/5(0%)	0/6(0%)	-
Kidney arteriosclerosis	4/11 (36%)	1/5 (20%)	3/6 (50%)	0.064
ADIPOSE	1/11 (30/0)	1/5 (2070)	5/0 (50/0)	0.004
Fat necrosis	10/21 (48%)	6/8 (75%)	4/13 (31%)	0.049
Fat fibrin	0/21(0%)	0/8 (0%)	0/13 (0%)	-
Fat unremarked	11/21 (52)	2/8 (25%)	9/13 (69%)	0.049
	11/21 (22)		2110 (0) /01	

*Histopathology was not performed on all the biopsy samples.

Table S3. Electron microscopy data of the Delta cohort.

Histology Tissue	All patients n=17*	culture- positive patients n=7	culture- negative patients n=10	p-value
LUNG				
Pneumocyte vacuolation	13/17 (76%)	6/7 (86%)	7/10 (70%)	0.452
Endothelial vacuolation	3/17 (18%)	2/7 (29%)	1/10 (10%)	0.323
Endothelial swelling	13/17 (76%)	6/7 (86%)	7/10 (70%)	0.452
Activated capillary monocytes	1/17 (6%)	0/7 (0%)	1/10 (10%)	0.389
Pneumocyte detachment	15/17 (88%)	7/7 (100%)	8/10 (80%)	0.208
Collagen deposits	11/16 (69%)	5/6 (83%)	6/10 (60%)	0.330
HEART				
Mitochondrial hypoxic changes	12/12 (100%)	6/6 (100%)	6/6 (100%)	-
Myocyte atrophy and wrinkling	11/11 (100%)	6/6 (100%)	5/5 (100%)	-
Lipofuscin	7/11 (64%)	5/6 (83%)	2/5 (40%)	0.137
Swollen endothelial	10/11 (91%)	6/6 (100%)	4/5 (80%)	0.251
Fragmented red blood cells	4/11 (36%)	4/6 (57%)	0/5 (0%)	0.022
Myofibrillar disruption	5/11 (45%)	4/6 (57%)	1/5 (20%)	0.122
LIVER				
Swollen/hypoxic mitochondria	15/15 (100%)	6/6 (100%)	9/9 (100%)	-
Increased Kupffer	2/15 (13%)	1/6 (17%)	1/9 (11%)	0.757
Steatosis	7/15 (47%)	2/6 (33%)	5/9 (56%)	0.398
Haemophagocytosis	10/15 (67%)	4/6 (57%)	6/9 (67%)	1
Detached of endothelial cells	7/15 (47%)	3/6 (50%)	4/9 (44%)	0.833
Lipidized stellate cells	7/15 (47%)	3/6 (50%)	4/9 (44%)	0.833
EM liver cholestasis	2/14 (14%)	1/6 (17%)	1/8 (13%)	0.826
ADIPOSE				
Normal mitochondria	3/14 (21%)	0/6 (0%)	3/8 (38%)	0.091
Slightly enlarged mitochondria	5/14 (36%)	4/6 (57%)	1/8 (13%)	0.036
Enlarged mitochondria	6/14 (43%)	2/6 (33%)	4/8 (50%)	0.533
Swollen endothelial cells present	9/11 (82%)	4/4 (100%)	5/7 (71%)	0.237

*EM was only performed on biopsy samples in the Delta cohort.



Figure S7. Gene expression profile in the culture-negative and culture-positive groups cluster into distinct groups. PCA plot (**A**) and heatmap (**B**) showing that distinct genes are differentially regulated in the culture-positive and culture-negative groups.

Table S4. Whole genome sequencing results of the viral variants from the study cohort. Only 6 culture-negative and 6 culturepositive samples were available for sequencing because either the viral load was too low (Ct>30) or the sample was not available. It was therefore impossible to perform comparative analysis between the 2 groups because of the small sample number. Data was analysed and sequences aligned using the Stanford University Coronavirus Antiviral and Resistance Database (available at: https://covdb.stanford.edu/)

Patient ID*	Source of sample	Varian t	Linea ge	Sub- lineage	Gene	Unique mutations	Comments	Ref
						(found in <0.01% of		
						genomes)		
				-				
WITS 1210	Lung culture supernatant	Beta	20B	B.1.1	-	None		
WITS 12068	Lung culture supernatant	Beta	20H	B.1.3.51	-	None		
WITS 12115	Lung culture supernatant	Beta	20H	B.1.351	-	None		
UCT 001	NPS	Alpha	20I	B1.1.7	-	None		
UCT 004	NPS	Beta	20H	B1.351				
UCT 028	NPS	Delta	21J	AY6	-	None		
UCT 016	NPS	Delta	21J	AY91				
UCT 008	NPS	Delta	21J	AY32	Papain-like protease (PLpro)	C55C*W E113EAGV E115ED C118C*W		
					Helicase (nsp13)	P593DE R594X		
					mRNA capping protein (nsp 14)	K433KN P443PAST K469KMRT A471APST		
					Membrane (M)	S211R S212*DEHQ Y S213X		
UCT 012	NPS	Delta	21J	AY32	-	None		
UCT 018	NPS	Delta	21J	B1.617.2	Main protease (PLpro)	A191T	A191T is a reported resistance mutation against 3C- like protease inhibitor, i.e. nirmatrelvir.	8
					RdRP	H650N		
					Spike	V16VFIL K77E		
					Nucleocapsi d	S255A		
UCT 022	NPS	Delta	21J	AY32	-	Sequence missing		

UCT 024	NPS	Delta	21J	AY6	Main protease (PLpro)	N1454NIST	
					Helicase (nsp13)	F587L T588TIR	
					mRNA capping protein (nsp 14)	M72X R485DE H486X H487X	
					Accessory protein (ORF3a)	K21R D22D*EHQY L94LV	

Table S5. Transcriptomic analysis showing genes upregulated in the culture-positive cohort relative to the culture-negative cohort.

ENZ_ID	Abbreviation	Gene name	logFC	logCPM	p value	FDR
26585	GREM1	Gremlin 1, DAN family BMP antagonist	3.05	5.43	1.99E-06	0.032
27111	SDCBP2	Syndecan binding protein 2	1.67	3.38	6.06E-06	0.032
374	AREG	Amphiregulin	2.10	4.96	9.19E-06	0.032
5055	SERPINB2	Serpin family B member 2	4.43	2.50	1.07E-05	0.032
771	CA12	Carbonic anhydrase 12	2.10	5.34	1.22E-05	0.032
134285	TMEM171	Transmembrane protein 171	2.22	-0.55	1.28E-05	0.032
9982	FGFBP1	Fibroblast growth factor binding protein 1	2.65	2.07	1.63E-05	0.032
338328	GPIHBP1	Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1	-2.25	2.63	1.65E-05	0.032
80320	SP6	Sp6 transcription factor	1.67	1.80	1.88E-05	0.032
1E+08	RASA4B	RAS p21 protein activator 4B	-2.81	2.91	2.00E-05	0.032
1E+08	FAM225B	Family with sequence similarity 225 member B (non-protein coding)	-2.35	-1.23	2.08E-05	0.032
1847	DUSP5	Dual specificity phosphatase 5	1.95	5.27	2.29E-05	0.032
57126	CD177	CD177 molecule	4.15	5.53	2.80E-05	0.034
2537	IFI6	Interferon alpha inducible protein 6	2.22	7.36	2.86E-05	0.034
4915	NTRK2	Neurotrophic receptor tyrosine kinase 2	-2.44	4.68	4.73E-05	0.050
3172	HNF4A	Hepatocyte nuclear factor 4 alpha	-2.44	-0.75	4.74E-05	0.050
6853	SYN1	Synapsin I	1.95	2.27	6.03E-05	0.060
22943	DKK1	Dickkopf WNT signalling pathway inhibitor 1	3.06	2.75	7.50E-05	0.068
2827	GPR3	G protein-coupled receptor 3	2.07	0.53	7.63E-05	0.068
6355	CCL8	C-C motif chemokine ligand 8	3.65	4.38	8.74E-05	0.069

Table S6A. Pathways upregulated in the culture-positive cohort relative to the culture-negative cohort.

GO.ID	Pathway	Total number of genes associated with the pathway	Enrichment score	NES	p value	FDR
GO:0045087	Innate immune response	644	0,462041652	2,23077102	3,19E-26	1,95E-22
GO:0009617	Response to bacterium	502	0,436586937	2,063633461	1,46E-16	2,30E-13
GO:0006954	Inflammatory response	666	0,397117204	1,910719799	1,84E-16	2,30E-13
GO:0009615	Response to virus	337	0,482017466	2,192737214	4,76E-16	4,15E-13
GO:0034097	Response to cytokine	784	0,378837973	1,853887449	4,57E-16	4,15E-13

GO:0042742	Defence response to bacterium	187	0,57065003	2,468893487	2,87E-15	1,95E-12
GO:0097529	Myeloid leukocyte migration	197	0,560938069	2,429088511	7,89E-15	4,82E-12
GO:0071345	Cellular response to cytokine stimulus	700	0,379135852	1,832624826	1,29E-14	7,19E-12
GO:0060326	Cell chemotaxis	260	0,505415546	2,244480472	3,87E-14	1,69E-11
GO:0030595	Leukocyte chemotaxis	199	0,543874673	2,355877738	7,37E-14	2,81E-11
GO:1903047	Mitotic cell cycle process	679	0,37365134	1,802308085	9,44E-14	3,39E-11
GO:0042330	Taxis	521	0,406071568	1,918906559	1,71E-13	5,80E-11
GO:0050900	Leukocyte migration	334	0,461740475	2,094951262	1,90E-13	6,01E-11
GO:0006935	Chemotaxis	519	0,406436107	1,934745764	1,97E-13	6,01E-11
GO:0000280	Nuclear division	380	0,433965649	1,999760733	8,85E-13	2,35E-10
GO:0019221	Cytokine-mediated signalling pathway	401	0,424428923	1,972848247	2,15E-12	5,46E-10
GO:0007059	Chromosome segregation	305	0,457222273	2,071558403	2,72E-12	6,65E-10
GO:0051301	Cell division	573	0,383696506	1,825281074	3,41E-12	7,87E-10
GO:2000147	Positive regulation of cell motility	507	0,386349508	1,825320536	7,25E-12	1,53E-09
GO:0002237	Response to molecule of bacterial origin	294	0,453670477	2,036098196	1,01E-11	2,05E-09

Table S6B. Other pathways of interest upregulated in the culture-positive cohort relative to the culture-negative cohort.

		Total number of genes associated			
GO.ID	Pathway	with the pathway	Enrichment score	NES	FDR
GO:04657	IL-17 signalling pathway	81	0,635892	2.380892	1,53E-07
GO:0002456	T-cell-mediated immunity	96	0,478752825	1,850434828	1,1E-03
GO:0002825	Regulation of T-helper 1 type immune response	25	0,576145234	1,920646442	1,2E-3
GO:0035710	CD4-positive, alpha-beta T cell activation	89	0,470392439	1,801972021	2,1E-03
GO:0035743	CD4-positive, alpha-beta T cell cytokine production	15	0,774743052	2,055120611	3E-03
GO:0002726	Positive regulation of T cell cytokine production	24	0,683190625	2,000311209	3,4E-03
GO:0042110	T cell activation	448	0,294698908	1,379497641	3,5E-03
GO:2000514	Regulation of CD4-positive, alpha-beta T cell activation	56	0,519437379	1,853870959	5,8-03
GO:0002711	Positive regulation of T cell mediated immunity	49	0,543959461	1,869533223	6,7E-3
GO:0042088	Th1 immune response	41	0,576145234	1,920646442	6,7E-03
GO:0002709	Regulation of T-cell mediated immunity	76	0,686930834	2,050809398	7,3E-03

GO:0002369	T-cell cytokine production	34	0,610833263	1,94794025	9,1E-3
GO:0002724	Regulation of T cell cytokine production	34	0,610833263	1,94794025	9,1E-03
GO:0050868	Negative regulation of T cell activation	109	0,413862853	1,63976229	1,1E-02

Table S6C. Genes associated with regulatory pathways of are not uo- or downregulated in the culture-positive cohort relative to the culture-negative cohort.

ENZ ID	Gene	LogFC	p-value	FDR
5133	PD-1	-0,580384672	0,352556526	0,875617669
64115	VISTA	0,195588418	0,601343382	0,941688131
84868	TIM-3	0,243920799	0,568480759	0,936258857
1493	CTLA-4	0,100226405	0,868488938	0,987403587
940	CD28	-0,515589978	0,192859859	0,773804865
945	CD33	-0,047967186	0,910411079	0,991670954
3559	CD25	-0,703108858	0,154569866	0,728675358
50943	FOXP3	-0,918764993	0,158003877	0,732211968

Supplementary results pertaining to the transcriptomic analysis.

We obtained lung biopsy samples within ~2hrs postmortem to preserve the transcriptional signature. This is well within the postmortem interval (PMI) reported to preserve RNA stability and integrity in the lung ¹⁻³. One study reported that RNA stability could be preserved after a PMI as long as 41hrs ¹. The lung-culture-positive group express higher levels of carbonic anhydrase 12 (CA12) than the lung culture-negative group (Figure 5, S8 and Table S5). This protein induces a phenotype similar to high-altitude pulmonary oedema with a decreased ratio of arterial oxygen, partial pressure to fractional inspired oxygen, and a reduction of the carbon dioxide levels. This was associated increased tachypnoea and fibrinogen levels/fibrin formation and the presence of hypoxia leading to ARDS.

Another gene that was highly overexpressed in the culture-positive cohort was CD177, a glycosylphosphatidylinositol (GPI)-anchored protein expressed by neutrophils. CD177 plays a key role in neutrophil activation, transmigration and adhesion to the endothelium and are associated with the severity of Covid-19 disease ⁴ (Figure 5, S8 and Table S5). Fu et al ⁵ reported that neutrophil chemotaxis, infiltration of endothelial cells, and extravasation into alveolar spaces have been described in lung autopsies from deceased patients with COVID-19⁶. CD177 was recently identified by proteomics in bronchoalveolar lavage of COVID-19 patients ⁶ which supports our data of an upregulation of CD177 in our

decedents. Our histopathological data support these findings where we show that the lung culture-positive group have higher infiltration of neutrophils into the alveoli than the ling-culture negative group.

Syndecan binding protein 2 was significantly upregulated in the culture-positive versus the culture-negative group (Figure 5, S8 and Table S5). The protein is a family member of the syndecans (SDC) which are transmembrane proteoglycans that facilitate the cellular entry of SARS-CoV-2⁷. Endothelial cells express SDC2 and during virus internalization, syndecans colocalize with ACE2, suggesting a jointly shared internalization pathway. Hudak et al ⁷ reported that entry via SDCs enabled efficient gene transduction with SARS-CoV-2 pseudovirus which implied that SDC-mediated internalisation pathway maintained the viral particles biological activity. Viruses that target SDCs in the lung may therefore interfere with SDC-dependent signalling as inhibitors to both ACE2 and syndecan reduced the cellular entry of SARS-CoV-2, thus supporting the complex nature of internalization.

The culture-positive group, compared to the culture-negative group, are associated with the enrichment of inflammatory, innate immune and enhanced SARS-CoV-2 entry pathways



Figure S8. The culture-positive group expressed higher levels of genes associated with inflammatory, innate immunity and enhanced SARS-CoV-2 cellular entry pathways compared to the culture-negative cohort. Volcano plots showing the pathways (A) and individual genes (B and C) upregulated in the culture-positive versus the culture-negative cohort. Gene expression profile of individual genes upregulated in the cytokine signalling (D), innate immune (E) and enhanced SARS-CoV-2 cellular entry (F) pathways in the culture-positive versus culture-negative cohort. Cyto = cytokine signalling, def. resp.virus = defence of respiratory virus, innate = innate immunology, inflame = inflammatory response, vir_ent=viral entry. The red line represents FDR<0.05 and the black dotted

















Figure S9. Key pathways up (red) and downregulated (green) in the culture-positive versus culture-negative decedents. Figures were constructed using the Kyoto Encyclopaedia of Genes and Genomes Database.

Supplementaty references.

- 1. De Paepe, M.E., et al. Postmortem RNA and protein stability in perinatal human lungs. *Diagn Mol Pathol* **11**, 170-176 (2002).
- 2. Fan, J., et al. Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. *Oncotarget* **7**, 66906-66921 (2016).
- 3. Floros, J., et al. The utility of postmortem lung for RNA studies; variability and correlation of the expression of surfactant proteins in human lung. *Exp Lung Res* **17**, 91-104 (1991).
- 4. Levy, Y., *et al.* CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. *iScience* **24**, 102711 (2021).
- 5. Fu, J., *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. *Thromb Res* **192**, 3-8 (2020).
- 6. Aschenbrenner, A.C., *et al.* Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. *Genome Med* **13**, 7 (2021).
- 7. Hudak, A., Letoha, A., Szilak, L. & Letoha, T. Contribution of syndecans to the cellular entry of SARS-CoV-2. *Int J Mol Sci* **22**(2021).
- 8. Noske G D, d.S.S.E., de Godoy M O, Dolci I, Fernandes R S, Guido R V C, Sjö P, Oliva G. Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 Main Protease naturally occurring polymorphisms. *bioRxiv* (2022).